NASDAQ:ECOR

electroCore Competitors

$1.96

-0.10 (-4.85 %)

(As of 04/9/2021 12:00 AM ET)

Add

Compare

Today's Range

$1.96

Now: $1.96▼

$2.06

50-Day Range

$1.96

MA: $2.20▼

$2.81

52-Week Range

$0.74

Now: $1.96▼

$3.63

Volume892,696 shs

Average Volume4.05 million shs

Market Capitalization$95.01 million

P/E RatioN/A

Dividend YieldN/A

Beta1.62

electroCore (NASDAQ:ECOR) Vs. EDAP, EYES, BSGM, FONR, IRIX, and NDRA

Should you be buying ECOR stock or one of its competitors? Companies in the industry of "electromedical equipment" are considered alternatives and competitors to electroCore, including Edap Tms (EDAP), Second Sight Medical Products (EYES), BioSig Technologies (BSGM), FONAR (FONR), IRIDEX (IRIX), and ENDRA Life Sciences (NDRA).

electroCore vs. Edap Tms Stock

Edap Tms (NASDAQ:EDAP) and electroCore (NASDAQ:ECOR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, dividends and analyst recommendations.

Earnings & Valuation

This table compares Edap Tms and electroCore's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edap Tms	$50.23 million	5.30	$1.69 million	$0.06	152.33
electroCore	$2.39 million	39.76	$-45,150,000.00	($1.54)	-1.27

Edap Tms has higher revenue and earnings than electroCore. electroCore is trading at a lower price-to-earnings ratio than Edap Tms, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

5.5% of electroCore shares are held by institutional investors. 24.9% of electroCore shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Edap Tms and electroCore's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Edap Tms	-4.03%	-11.54%	-5.78%
electroCore	-792.01%	-109.15%	-79.64%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Edap Tms and electroCore, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edap Tms	0	0	3	0	3.00
electroCore	0	0	5	0	3.00

Edap Tms presently has a consensus target price of $12.50, indicating a potential upside of 36.76%. electroCore has a consensus target price of $3.70, indicating a potential upside of 88.78%. Given electroCore's higher possible upside, analysts plainly believe electroCore is more favorable than Edap Tms.

Risk and Volatility

Edap Tms has a beta of 1.92, meaning that its share price is 92% more volatile than the S&P 500. Comparatively, electroCore has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500.

Summary

Edap Tms beats electroCore on 7 of the 13 factors compared between the two stocks.

electroCore vs. Second Sight Medical Products Stock

Second Sight Medical Products (NASDAQ:EYES) and electroCore (NASDAQ:ECOR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, dividends and analyst recommendations.

Earnings & Valuation

This table compares Second Sight Medical Products and electroCore's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Second Sight Medical Products	$3.38 million	60.95	$-33,590,000.00	($1.91)	-4.64
electroCore	$2.39 million	39.76	$-45,150,000.00	($1.54)	-1.27

Second Sight Medical Products has higher revenue and earnings than electroCore. Second Sight Medical Products is trading at a lower price-to-earnings ratio than electroCore, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

4.1% of Second Sight Medical Products shares are held by institutional investors. Comparatively, 5.5% of electroCore shares are held by institutional investors. 67.5% of Second Sight Medical Products shares are held by company insiders. Comparatively, 24.9% of electroCore shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Second Sight Medical Products and electroCore's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Second Sight Medical Products	N/A	-977.63%	-291.02%
electroCore	-792.01%	-109.15%	-79.64%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Second Sight Medical Products and electroCore, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Second Sight Medical Products	0	0	0	0	N/A
electroCore	0	0	5	0	3.00

electroCore has a consensus target price of $3.70, indicating a potential upside of 88.78%. Given electroCore's higher possible upside, analysts plainly believe electroCore is more favorable than Second Sight Medical Products.

Risk and Volatility

Second Sight Medical Products has a beta of 2.49, meaning that its share price is 149% more volatile than the S&P 500. Comparatively, electroCore has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500.

Summary

electroCore beats Second Sight Medical Products on 7 of the 13 factors compared between the two stocks.

electroCore vs. BioSig Technologies Stock

BioSig Technologies (NASDAQ:BSGM) and electroCore (NASDAQ:ECOR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, dividends and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for BioSig Technologies and electroCore, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioSig Technologies	0	0	0	0	N/A
electroCore	0	0	5	0	3.00

Earnings & Valuation

This table compares BioSig Technologies and electroCore's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioSig Technologies	N/A	N/A	$-34,060,000.00	N/A	N/A
electroCore	$2.39 million	39.76	$-45,150,000.00	($1.54)	-1.27

BioSig Technologies has higher earnings, but lower revenue than electroCore.

Risk and Volatility

BioSig Technologies has a beta of 1.83, meaning that its share price is 83% more volatile than the S&P 500. Comparatively, electroCore has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500.

Insider & Institutional Ownership

18.3% of BioSig Technologies shares are held by institutional investors. Comparatively, 5.5% of electroCore shares are held by institutional investors. 19.5% of BioSig Technologies shares are held by company insiders. Comparatively, 24.9% of electroCore shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares BioSig Technologies and electroCore's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioSig Technologies	N/A	-244.64%	-213.88%
electroCore	-792.01%	-109.15%	-79.64%

Summary

electroCore beats BioSig Technologies on 6 of the 10 factors compared between the two stocks.

electroCore vs. FONAR Stock

electroCore (NASDAQ:ECOR) and FONAR (NASDAQ:FONR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations for electroCore and FONAR, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
electroCore	0	0	5	0	3.00
FONAR	0	0	0	0	N/A

electroCore presently has a consensus target price of $3.70, indicating a potential upside of 88.78%. Given electroCore's higher possible upside, equities research analysts clearly believe electroCore is more favorable than FONAR.

Valuation & Earnings

This table compares electroCore and FONAR's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
electroCore	$2.39 million	39.76	$-45,150,000.00	($1.54)	-1.27
FONAR	$85.69 million	1.42	$8.24 million	N/A	N/A

FONAR has higher revenue and earnings than electroCore.

Risk and Volatility

electroCore has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500. Comparatively, FONAR has a beta of 1.07, meaning that its share price is 7% more volatile than the S&P 500.

Insider and Institutional Ownership

5.5% of electroCore shares are held by institutional investors. Comparatively, 62.1% of FONAR shares are held by institutional investors. 24.9% of electroCore shares are held by company insiders. Comparatively, 8.6% of FONAR shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares electroCore and FONAR's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
electroCore	-792.01%	-109.15%	-79.64%
FONAR	8.28%	5.57%	3.99%

Summary

FONAR beats electroCore on 7 of the 12 factors compared between the two stocks.

electroCore vs. IRIDEX Stock

electroCore (NASDAQ:ECOR) and IRIDEX (NASDAQ:IRIX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations for electroCore and IRIDEX, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
electroCore	0	0	5	0	3.00
IRIDEX	0	0	2	0	3.00

electroCore presently has a consensus target price of $3.70, indicating a potential upside of 88.78%. IRIDEX has a consensus target price of $6.50, indicating a potential downside of 10.96%. Given electroCore's higher possible upside, equities research analysts clearly believe electroCore is more favorable than IRIDEX.

Valuation & Earnings

This table compares electroCore and IRIDEX's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
electroCore	$2.39 million	39.76	$-45,150,000.00	($1.54)	-1.27
IRIDEX	$43.45 million	2.61	$-8,810,000.00	($0.64)	-11.41

IRIDEX has higher revenue and earnings than electroCore. IRIDEX is trading at a lower price-to-earnings ratio than electroCore, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

electroCore has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500. Comparatively, IRIDEX has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500.

Insider and Institutional Ownership

5.5% of electroCore shares are held by institutional investors. Comparatively, 32.6% of IRIDEX shares are held by institutional investors. 24.9% of electroCore shares are held by company insiders. Comparatively, 2.0% of IRIDEX shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares electroCore and IRIDEX's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
electroCore	-792.01%	-109.15%	-79.64%
IRIDEX	-21.54%	-38.60%	-24.99%

Summary

IRIDEX beats electroCore on 7 of the 13 factors compared between the two stocks.

electroCore vs. ENDRA Life Sciences Stock

electroCore (NASDAQ:ECOR) and ENDRA Life Sciences (NASDAQ:NDRA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations for electroCore and ENDRA Life Sciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
electroCore	0	0	5	0	3.00
ENDRA Life Sciences	0	0	0	0	N/A

Valuation & Earnings

This table compares electroCore and ENDRA Life Sciences' top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
electroCore	$2.39 million	39.76	$-45,150,000.00	($1.54)	-1.27
ENDRA Life Sciences	$10,000.00	10,566.40	$-13,310,000.00	($2.34)	-1.09

ENDRA Life Sciences has lower revenue, but higher earnings than electroCore. electroCore is trading at a lower price-to-earnings ratio than ENDRA Life Sciences, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

electroCore has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500. Comparatively, ENDRA Life Sciences has a beta of 1.6, meaning that its share price is 60% more volatile than the S&P 500.

Insider and Institutional Ownership

5.5% of electroCore shares are held by institutional investors. Comparatively, 2.8% of ENDRA Life Sciences shares are held by institutional investors. 24.9% of electroCore shares are held by company insiders. Comparatively, 9.6% of ENDRA Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares electroCore and ENDRA Life Sciences' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
electroCore	-792.01%	-109.15%	-79.64%
ENDRA Life Sciences	N/A	-492.76%	-288.58%

Summary

electroCore beats ENDRA Life Sciences on 9 of the 13 factors compared between the two stocks.